Document is current
Any future updates will be listed below
-
Authors
Choo, Zi-Ning
Behr, Julie M.
Deshpande, Aditya
Hadi, Kevin
Yao, Xiaotong
Tian, Huasong
Takai, Kaori
Zakusilo, George
Rosiene, Joel http://orcid.org/0000-0002-8610-370X
Da Cruz Paula, Arnaud http://orcid.org/0000-0001-7694-8760
Weigelt, Britta http://orcid.org/0000-0001-9927-1270
Setton, Jeremy
Riaz, Nadeem http://orcid.org/0000-0001-9873-5862
Powell, Simon N. http://orcid.org/0000-0002-8183-4765
Busam, Klaus http://orcid.org/0000-0003-0888-9601
Shoushtari, Alexander N.
Ariyan, Charlotte
Reis-Filho, Jorge http://orcid.org/0000-0003-2969-3173
de Lange, Titia http://orcid.org/0000-0002-9267-367X
Imieliński, Marcin http://orcid.org/0000-0002-2211-4741
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U24-CA15020, U24-CA264032, U24-CA15020, U24-CA264032, F31-CA232465, U24-CA15020, U24-CA264032, U24-CA264032, U24-CA15020, U24-CA15020, U24-CA264032, R35-CA210036, F30CA268747, R35-CA210036)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32GM007739, T32GM007739)
Starr Foundation (II11-0051, II11-0051)
- License Information
-
More Information
Article History
Received: 1 June 2021
Accepted: 19 September 2023
First Online: 9 November 2023
Competing interests
: J.R.-F. reports receiving personal or consultancy fees from Goldman Sachs, Bain Capital, REPARE Therapeutics and Paige.AI, membership of the scientific advisory board of VolitionRx, REPARE Therapeutics, Personalis and Paige.AI, membership of the board of directors of Grupo Oncoclinicas and ad hoc membership of the scientific advisory board of Roche Tissue Diagnostics, Ventana Medical Systems, Novartis, Genentech, Merck, Daiichi Sankyo and AstraZeneca, outside the scope of this study. B.W. reports ad hoc membership of the scientific advisory board of REPARE Therapeutics outside the scope of this study. S.N.P. reports consulting fees from the following companies outside the scope of this study: Varian Medical Systems, Philips Healthcare and AstraZeneca, as well as research funding from Philips Healthcare and Varian Medical Systems. T.d.L. is on the scientific advisory board of Calico Life Sciences. M.I. is on the scientific advisory board of ImmPACT Bio. The remaining authors declare no competing interests.
